Table 1.
Marker | Unadjusted HR (95% CI) | Adjusted† HR (95% CI) | Adjusted‡ HR (95% CI) | Adjusted/negative receptors§ HR (95% CI) | Adjusted/positive receptors§ HR (95% CI) |
---|---|---|---|---|---|
Disease-free survival | |||||
p27 | 1.31 (1.10 to 1.57) | 1.32 (1.10 to 1.57) | 1.18 (0.98 to 1.42) | 1.06 (0.81 to 1.39) | 1.27 (0.99 to 1.63) |
cyclin E | 1.09 (0.92 to 1.29) | 1.13 (0.95 to 1.34) | 1.02 (0.85 to 1.22) | 0.95 (0.74 to 1.21) | 1.13 (0.88 to 1.46) |
Overall survival | |||||
p27 | 1.50 (1.21 to 1.86) | 1.51 (1.22 to 1.87) | 1.31 (1.05 to 1.64) | 1.19 (0.86 to 1.64) | 1.42 (1.05 to 1.94) |
cyclin E | 1.12 (0.91 to 1.38) | 1.17 (0.95 to 1.44) | 1.03 (0.83 to 1.27) | 0.87 (0.65 to 1.16) | 1.25 (0.92 to 1.71) |
HR = hazard ratio; CI = confidence interval. Overall survival was defined as the time to death from any cause. Disease-free survival was defined as the time to first recurrence (local, regional, or distant), new primary cancer in the contralateral breast, or death due to any cause.
Analyses were adjusted for tumor size (<2 cm, 2–5 cm, or >5 cm), number of positive lymph nodes (0, 1, 2, or 3), menopausal status, and randomized treatment but not receptor status.
Analyses were adjusted for tumor size (<2 cm, 2–5 cm, or >5 cm), number of positive lymph nodes (0, 1, 2, or 3), menopausal status, randomized treatment, and receptor status (both estrogen receptor and progesterone receptor negative vs. either positive).
Analyses were adjusted for tumor size, number of positive lymph nodes, menopausal status, and treatment and then separately analyzed by receptor status.